Related Experiment Video

Updated: Jul 23, 2026

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

Effects of claritromycin on inflammatory parameters and clinical conditions in children with bronchiectasis

E Yalçin1, N Kiper, U Ozçelik

  • 1Chest Diseases Unit, Department of Pediatrics, Hacettepe University Faculty of Medicine, 06100-Ankara, Turkey. ebruy@hacettepe.edu.tr

Journal of Clinical Pharmacy and Therapeutics
|February 16, 2006
PubMed
Abstract

Insights

Clarithromycin (CAM) reduced lung inflammation markers and sputum in children with bronchiectasis. While laboratory results improved, clinical benefits require further study for long-term efficacy.

Area of Science:

  • Pediatric Pulmonology
  • Pharmacology
  • Immunology

Background:

  • Macrolides possess significant immunoregulatory and anti-inflammatory properties beyond their antibacterial effects.
  • Macrolides are commonly used for diffuse panbronchiolitis and cystic fibrosis (CF).

Purpose of the Study:

  • To assess the impact of clarithromycin (CAM) on inflammation, pulmonary function, and sputum production in pediatric bronchiectasis.
  • Investigate changes in bronchoalveolar lavage (BAL) fluid IL-8, TNF-alpha, IL-10, and cell profiles.

Main Methods:

  • Seventeen pediatric patients with bronchiectasis received CAM and supportive care for 3 months.
  • A control group of 17 patients received only supportive therapies.
  • Evaluated BAL fluid inflammatory markers, cell counts, pulmonary function, and sputum production.

Main Results:

  • CAM treatment significantly decreased IL-8 levels, total cell count, and neutrophil ratios in BAL fluid.
  • A significant increase in BAL fluid macrophage ratios was observed in the CAM group.
  • Daily sputum production was significantly reduced with CAM treatment.
  • Pulmonary function test parameters did not show significant differences.

Conclusions:

  • CAM effectively reduces inflammatory processes in pediatric bronchiectasis, as indicated by laboratory improvements.
  • No significant short-term clinical improvement was observed.
  • Long-term efficacy and clinical benefits of CAM require further investigation and validation.

Related Concept Videos

Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Asthma I: Introduction01:28

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
Asthma III: Clinical Manifestations01:13

Asthma III: Clinical Manifestations

Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...